BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36765492)

  • 21. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
    Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
    [No Abstract]   [Full Text] [Related]  

  • 22. Liquid extramedullary disease in multiple myeloma strongly predicts a poor prognosis and is associated with bortezomib resistance gene upregulation.
    Ji J; Guo R; Ma J; Cui Y; Li Y; Sun Z; Li J; Fan L; Qu X
    Clin Chim Acta; 2023 Aug; 548():117497. PubMed ID: 37479009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
    Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: A real-world analysis.
    Chen H; Shi H; Zhou N; Yu W; Wu L; Peng R; Wei W; Wang D; Zhou F
    Eur J Haematol; 2023 Mar; 110(3):229-235. PubMed ID: 36366975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Predictive Value of Pre-treatment Serum Uric Acid Level for Prognosis in Newly Diagnosed Patients with Multiple Myeloma].
    Xu SQ; Zhao P; Wang ZH; Deng H; Zhang L; Wei J; Zou XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1216-1223. PubMed ID: 34362505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease].
    Chao Y; Fan L; Gao XY; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):115-121. PubMed ID: 33554807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
    Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
    Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients.
    Yue X; He D; Zheng G; Yang Y; Han X; Li Y; Zhao Y; Wu W; Chen Q; Zhang E; Cai Z; He J
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
    Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
    Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].
    Zhao JT; Jiang XY; Yang C; Chen M; Lan XL; Du JH; Zhou DB; Zhuang JL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):295-301. PubMed ID: 33979973
    [No Abstract]   [Full Text] [Related]  

  • 31. Diagnosis and treatment of multiple myeloma in Hunan Province.
    Liu F; Cheng Q; Song K; Yu H; Li J; Zhang H; Hu G; Zhou M; Wang J; Ding Z; Luo Z; Peng T; Ding L; Zhao L; Liu J; He Y; Peng H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 47(4):497-504. PubMed ID: 35545345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study].
    Xu Y; Shen XX; Jin YY; Li JY; Chen LJ; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):749-754. PubMed ID: 38049319
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
    Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical Characteristics of Multiple Myeloma Patients with Early Relapse].
    Chen T; Ji JM; Li YT; Fan L; Chen LJ; Li JY; Qu XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1144-1149. PubMed ID: 35981375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients.
    Cao Y; Gong Y; Zhou X; Sun C
    Hematology; 2023 Dec; 28(1):2208914. PubMed ID: 37145015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: A real-world validation study.
    Wang YT; Chu B; Zhou TG; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Zhao X; Wang MZ; Sun K; Bao L
    Front Oncol; 2023; 13():1110693. PubMed ID: 36969050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis.
    Bao L; Wang YT; Lu MQ; Chu B; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH; Liu X; Zhao X; Wang MZ; Chen Y; Hu WK
    Front Endocrinol (Lausanne); 2023; 14():1157969. PubMed ID: 37181039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
    Mao X; Yan W; Mery D; Liu J; Fan H; Xu J; Xu Y; Sui W; Deng S; Zou D; Du C; Yi S; van Rhee F; Barlogie B; Shaughnessy JD; Anderson KC; Zhan F; Qiu L; An G
    Am J Hematol; 2024 Apr; 99(4):523-533. PubMed ID: 38247315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical and cytogenetic characteristics of myeloma patients with overall survival less than 24 months].
    Zhuang J; Tang W; Li H; Chen M; Han B; Zhu T; Duan M; Li J; Zhang W; Xu Y; Wang S; Zhao Y; Zhou D
    Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(10):736-40. PubMed ID: 26080843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.